ConductScience.org, home

Paper40831663

Administration of Cilostazol Prior to Intravenous Alteplase for Acute Branch Atheromatous Disease: A Report of Three Cases.

Tanaka E and 4 others. Case Rep Neurol Med, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Administration of Cilostazol Prior to Intravenous Alteplase for Acute Branch Atheromatous Disease: A Report of Three Cases. Papers, record 40831663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40831663

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Administration of Cilostazol Prior to Intravenous Alteplase for Acute Branch Atheromatous Disease: A Report of Three Cases.
PubMed
Journal
Case Rep Neurol Med
PubMed
Year
2025
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-09-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tanaka EEijirouhttps://orcid.org/0000-0001-8122-007X
2Nagakane YYoshinarihttps://orcid.org/0000-0003-2203-7077
3Fukunaga DDaikihttps://orcid.org/0000-0002-1753-7598
4Nakashima DDaisuke
5Yamada TTakehiro

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123246192Treatment outcomes of tissue plasminogen activator infusion for branch atheromatous disease.J Stroke Cerebrovasc Dis2013https://conductscience.org/library/papers/23246192PubMed
232733357Efficacy and Safety of Intravenous Thrombolysis on Acute Branch Atheromatous Disease: A Retrospective Case-Control Study.Front Neurol2020https://conductscience.org/library/papers/32733357PubMed
322748820Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.Lancet2012https://conductscience.org/library/papers/22748820PubMed
42671793Intracranial branch atheromatous disease: a neglected, understudied, and underused concept.Neurology1989https://conductscience.org/library/papers/2671793PubMed
524820203Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2.Cerebrovasc Dis2014https://conductscience.org/library/papers/24820203PubMed
633882341Safety and efficacy of antiplatelet use before intravenous thrombolysis for acute Ischemic stroke.J Neurol Sci2021https://conductscience.org/library/papers/33882341PubMed
722632908
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
Lancet2012https://conductscience.org/library/papers/22632908PubMed
836757755Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.JAMA2023https://conductscience.org/library/papers/36757755PubMed
927728903Ultra-Early Combination Antiplatelet Therapy with Cilostazol for the Prevention of Branch Atheromatous Disease: A Multicenter Prospective Study.Cerebrovasc Dis Extra2016https://conductscience.org/library/papers/27728903PubMed
107477192Tissue plasminogen activator for acute ischemic stroke.N Engl J Med1995https://conductscience.org/library/papers/7477192PubMed
1127452127Intravenous tissue plasminogen activator in acute branch atheromatous disease: Does it prevent early neurological deterioration?J Clin Neurosci2016https://conductscience.org/library/papers/27452127PubMed
1221402390Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits.J Neurol Sci2011https://conductscience.org/library/papers/21402390PubMed
1320833591Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.Lancet Neurol2010https://conductscience.org/library/papers/20833591PubMed
1420056933Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.Stroke2010https://conductscience.org/library/papers/20056933PubMed
1532686168Prior Dual Antiplatelet Therapy and Thrombolysis in Acute Stroke.Ann Neurol2020https://conductscience.org/library/papers/32686168PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40831663

GET https://conductscience.org/api/papers/v1/40831663/authors